Title: Psoriasis and Comorbid Diseases Part I. Epidemiology

Authors: Junko Takeshita, MD, PhD, MSCE\textsuperscript{1,2}; Sungat Grewal, BS\textsuperscript{1}; Sinéad M. Langan, MB, BCh, BAO, MRCP, MSc, PhD\textsuperscript{3}; Nehal N. Mehta, MD, MSCE\textsuperscript{4}; Alexis Ogdie, MD, MSCE\textsuperscript{2,5}; Abby S. Van Voorhees, MD\textsuperscript{6}; Joel M. Gelfand, MD, MSCE\textsuperscript{1,2}.

Author Affiliations: Departments of Dermatology\textsuperscript{1}, Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics\textsuperscript{2}, and Division of Rheumatology\textsuperscript{5}, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; London School of Hygiene and Tropical Medicine and St. John’s Institute of Dermatology, London, United Kingdom\textsuperscript{3}; National Heart, Lung and Blood Institute, Bethesda, MD, USA\textsuperscript{4}; Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA\textsuperscript{6}.

Corresponding Author: Junko Takeshita, MD PhD MSCE, Department of Dermatology, University of Pennsylvania, 3400 Spruce St., 1104 Dulles, Philadelphia, PA 19104. Email: Junko.Takeshita@uphs.upenn.edu. Phone: 215-349-5551. Fax: 215-615-3127.

Funding/Support: This work was supported in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases K24AR064310 (Gelfand), T32AR007465-32 (Grewal), K23AR063764 (Ogdie), and K23AR068433 (Takeshita) grants, Dermatology Foundation Career Development Award (Takeshita), the Intramural Research Program at the National Institutes of Health, ZIAHL006193-02 (Mehta), and National Institute for Health Research Clinician Scientist
Fellowship, NIHR/CS/010/014 (Langan). The findings and conclusions in this report are those of
the authors and do not necessarily represent the views of the U.K. Department of Health.

Conflict of Interest Disclosures: Dr. Takeshita receives a research grant (to the Trusteees of the
University of Pennsylvania) from Pfizer and payment for continuing medical education work
related to psoriasis. Dr. Mehta is a full time U.S. Government employee. Dr. Ogdie receives
research grants from AbbVie (to the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis [GRAPPA]), Celgene (to GRAPPA), and Pfizer Inc. (to the Trustees of the
University of Pennsylvania and GRAPPA), and has served as a consultant for Novartis, receiving
honoraria. Dr. Van Voorhees has served as a consultant for AbbVie, Amgen, Aqua, AstraZeneca, Celgene, Corrona, Dermira, Janssen, Leo, Novartis, and Pfizer, receiving honoraria;
received a research grant from AbbVie; and has other relationship with Merck. Dr. Gelfand has
served as a consultant for AbbVie, AstraZeneca, Celgene Corp, Coherus, Eli Lilly, Janssen Biologics (formerly Centocor), Sanofi, Merck, Novartis Corp, Endo, and Pfizer Inc., receiving
honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from
AbbVie, Amgen, Eli Lilly, Janssen, Novartis Corp, Regeneron, and Pfizer Inc.; and received
payment for continuing medical education work related to psoriasis. Dr. Gelfand is a co-patent
holder of resiquimod for treatment of cutaneous T cell lymphoma.

Abstract word count: 106

Manuscript word count: 3492
Reference count: 162

Table count: 2

Figure count: 0